Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Despite numerous studies on cardioprotective effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs), there is limited evidence for n-3 PUFA-mediated effects, especially at its higher dose, on cardiovascular risk in patients with type 2 diabetes (DM2) and established atherosclerosis. Purpose: To investigate the effect of daily treatment with a higher dose (2 g) of n-3 PUFAs on platelet function, coagulation parameters, fibrin clot properties, markers of systemic inflammation and metabolic status, in patients with atherosclerotic vascular disease and DM2 who receive optimal medical therapy. Methods: We conducted a prospective, double-blind, placebo-controlled, randomized, double-center study, in which thrombin generation (plasma thrombogenic potential from automated thrombogram), fibrin clot properties (plasma fibrin clot permeability; lysis time), platelet aggregation (light transmission aggregometry with adenosine diphosphate and arachidonic acid used as agonists), HbA1c, insulin level, lipid profiles, leptin and adiponectin levels, as well as markers of systemic inflammation (i.e., hsCRP, IL-6, TNF-α, ICAM-1, VCAM-1, and myeloperoxidase) were determined at baseline and at 3 months after treatment with 2 g/day of n-3 PUFAs (n = 36) or placebo (n = 38). Moreover, we assessed serum fatty acids of the phospholipid fraction by gas chromatography both at baseline and at the end of the study. Results: Majority of patients were treated with optimal medical therapy and achieved recommended treatment targets. Despite higher serum levels of eicosapentaenoic acid (EPA) (by 204%; p < 0.001) and docosahexaenoic acid (DHA) (by 62%; p < 0.0001) in n-3 PUFA group at the end of treatment no changes in platelet aggregation, thrombin generation, fibrin clot properties or markers of systemic inflammation were observed. No intergroup differences in the insulin, HbA1c and lipid levels were found at the end of the study. There was no change in adiponectin and leptin in interventional group, however leptin increased in control group (p = 0.01), therefore after study period leptin levels were lower in the interventional group (p = 0.01). Additionally, resolvin D1 did not differ between interventional and control group. Conclusions: In conclusion, our study demonstrated that in patients with long-standing, well-controlled DM2 and atherosclerotic disease the treatment with a high dose of n-3 PUFAs (namely, 1 g/day of EPA and 1 g/day of DHA for 3 months) does not improve coagulation, metabolic, and inflammatory status when measured with the specified tests. The study was registered in ClinicalTrials.gov; identifier: NCT02178501. Registration date: April 12, 2014
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936 · cited 1×
“Currently, with advances in pharmacological and interventional cardiovascular (CV) therapy, the results of major randomized controlled trials (RCTs) have challenged the beneficial effect of n-3 PUFAs on CV risk [1, 2].”
Backgroundn–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Kabir, M., Skurnik, G., Naour, N., Pechtner, V., Meugnier, E., Rome, S., Quignard-Boulangé, A., Vidal, H., Slama, G., Clément, K., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1670 · Cited by 316
Chen, C., Yu, X., & Shao, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139565 · Cited by 133 · cited 1×
“[26] demonstrated that in DM2 n-3 PUFAs did not change HbA1c, fasting insulin, FPG, or postprandial glucose levels, which is in accordance with our results.”
ResultAlbert, B. B., Derraik, J. G. B., Brennan, C. M., Biggs, J. B., Smith, G. C., Garg, M. L., Cameron-Smith, D., Hofman, P. L., & Cutfield, W. S. (2014) · Scientific Reports · doi:10.1038/srep06697 · Cited by 105
Sawada, T., Tsubata, H., Hashimoto, N., Takabe, M., Miyata, T., Aoki, K., Yamashita, S., Oishi, S., Osue, T., Yokoi, K., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0437-y · Cited by 97
Wu, J. H. Y., Cahill, L. E., & Mozaffarian, D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3899 · Cited by 83
Cited by
The Influence of Dietary Fatty Acids on Immune Responses
Radzikowska, U., Rinaldi, A. O., Çelebi Sözener, Z., Karaguzel, D., Wojcik, M., Cypryk, K., Akdis, M., Akdis, C. A., & Sokolowska, M. (2019) · Nutrients · doi:10.3390/nu11122990 · Cited by 306
“The prevalence of type 2 diabetes (T2DM), a metabolic disorder that accounts for 90–95% of all diagnosed cases of diabetes in adults, is sharply increasing worldwide, especially in low and middle-income countries, with obesity and aging seen as the main driving forces [343].”
BackgroundInfluentialArachidonic acid metabolism in health and disease
Zhang, Y., Liu, Y., Sun, J., Zhang, W., Guo, Z., & Ma, Q. (2023) · MedComm · doi:10.1002/mco2.363 · Cited by 295
O’Mahoney, L. L., Matu, J., Price, O. J., Birch, K. M., Ajjan, R. A., Farrar, D., Tapp, R., West, D. J., Deighton, K., & Campbell, M. D. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0740-x · Cited by 157
“Nor were improvements observed in coagulation, metabolic, and inflammatory status in well-controlled patients with atherosclerotic vascular disease and T2DM [16].”
The effects of omega-3 fatty acids in type 2 diabetes: A systematic review and meta-analysis
Xiao, Y., Zhang, Q., Liao, X., Elbelt, U., & Weylandt, K. H. (2022) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102456 · Cited by 50
Metadata
- Authors
- Poreba, M., Mostowik, M., Siniarski, A., Golebiowska-Wiatrak, R., Malinowski, K. P., Haberka, M., Konduracka, E., Nessler, J., Undas, A., & Gajos, G.
- Venue
- Cardiovascular Diabetology
- Published
- 2017-04-14
- Volume
- 16
- Issue
- 1
- Pages
- 50-50
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2606036714
- Cited by
- 98
- References
- 7
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. https://app.cochat.ai/papers/10.1186/s12933-017-0523-9
- The paper
- Poreba, M., Mostowik, M., Siniarski, A., Golebiowska-Wiatrak, R., Malinowski, K. P., Haberka, M., Konduracka, E., Nessler, J., Undas, A., & Gajos, G. (2017). Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-017-0523-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.